Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy.
Plasma lipid and lipoprotein levels were measured at baseline and after 8 weeks of highly active antiretroviral therapy among patients receiving delavirdine with or without a protease inhibitor (PI). In patients receiving nucleoside reverse transcriptase inhibitors (NRTI) plus delavirdine, there was a statistically significant increase in cholesterol and HDL levels, whereas those receiving NRTI plus a PI had no significant change in their HDL levels. When delavirdine was combined with a PI, there was a more dramatic increase in both cholesterol and HDL concentrations.
Roberts
Afsoon D
AD
Division of Infectious Diseases, Department of Medicine, The George Washington University Medical Center, Washington DC, USA.
Liappis
Angelike P
AP
Chinn
Chris
C
Parenti
David M
DM
Muesing
Richard A
RA
Schuck
Suzanne Z
SZ
Hsia
Judy
J
Simon
Gary L
GL
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D020008:Delavirdine / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D015497:HIV-1; D006801:Humans; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D008055:Lipids; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D018894:Reverse Transcriptase Inhibitors; D002784:Cholesterol; D020008:Delavirdine